All In Biotech

Drug Trial Radar · NCT05245682

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck Cancer

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

10

Actual

Start

Feb 17, 2022

Primary completion

Jan 15, 2024

Study completion Jul 21, 2027

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Astex Pharmaceuticals, Inc.; National Cancer Institute (NCI)
First posted
Feb 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This early-phase trial tests the safety and side effects of a tolinapant given together with radiation therapy in treating patients with head and neck cancer for which the patient has not received treatment in the past (previously untreated), has spread to nearby tissue or lymph nodes (locally advanced) and cannot receive cisplatin (cisplatin-ineligible). Tolinapant may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tolinapant and radiation therapy may kill more tumor cells.

Conditions

  • Head and Neck Carcinoma of Unknown Primary
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
  • Locally Advanced Laryngeal Squamous Cell Carcinoma
  • Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
  • Locally Advanced Oropharyngeal Squamous Cell Carcinoma

Interventions

  • TolinapantDrug

    Given PO

  • Radiation TherapyRadiation

    Undergo radiation therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Tolinapant + Radiation (Number of Patients With Adverse Events Per CTCAE v5.0)Time frame: Up to 60 days post-treatment
  2. Feasibility of Tolinapant + Radiation (Number of Patients Able to Complete Treatment)Time frame: Upon completion of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University/Winship Cancer Institute

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.